Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw unusually-high trading volume on Friday . Approximately 117,193 shares traded hands during mid-day trading, a decline of 52% from the previous session’s volume of 241,954 shares.The stock last traded at $22.3835 and had previously closed at $22.11.

Analysts Set New Price Targets

CHGCY has been the subject of a number of research reports. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy”.

Chugai Pharmaceutical Price Performance

The company’s 50-day simple moving average is $23.40 and its 200 day simple moving average is $26.40. The firm has a market cap of $71.98 billion, a P/E ratio of 23.77 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Friday, July 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. The business had revenue of $2.14 billion during the quarter, compared to analysts’ expectations of $2.38 billion. Analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.